These findings suggest that there may be altered responses to oxidative stress in the tumors of patients with KEAP1/NFE2L2 mutations and may thus represent much-needed potential therapeutic targets for NSCLC. The gene discussed is NFE2L2; the disease is non-small cell lung carcinoma.